Momenta Pharmaceuticals leverages its proprietary technology to unlock the structural secrets of complex sugars and other complex mixtures. Our unique tools and approach to drug development have yielded a diversified product pipeline consisting of technology-enabled generic drugs, re-engineered drugs and novel drug candidates.
Spotlight
Momenta Pharmaceuticals Announces Appointment of
Bruce L. Downey to Board of Directors
CAMBRIDGE, MA — June 12, 2009 — Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced the appointment of Bruce L. Downey to its Board of Directors, effective June 11, 2009. Mr. Downey is the former Chairman and Chief Executive Officer of Barr Pharmaceuticals, Inc. and a former Chairman of the Generic Pharmaceutical Association (GPhA).
Momenta Pharmaceuticals Presents Preclinical Data for Novel Oncology Compound M402 at AACR Meeting
CAMBRIDGE, MA — April 20, 2009 — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced results from a preclinical study of its novel oncology drug candidate, M402.
More »
Momenta Featured in The New England Journal of Medicine
Read the article published online April 23, 2008 on the The New England Journal of Medicine website – “Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System”.
Click Here to Read the Article »
Momenta Featured in Nature Biotechnology
Read the article published online April 23, 2008 on the Nature Biotechnology website - "Oversulfated chondroitin sulfate is a contaminant in
heparin associated with adverse clinical events"
Click Here to Read the Article »
Momenta Featured in Nature
Read the article in the September 20, 2007 issue of Nature featuring Momenta Pharmaceuticals – “The Same but Different”.
Click Here to Read the Article »
FileOpen Plug-in for Adobe Acrobat/Reader required
Competitive Advantage
Momenta's unique business model creates near-term revenue opportunities that will fund longer-term discovery and development efforts. More »
